Many people with advanced Parkinson’s disease may actually not have widespread accumulation of toxic protein clumps known as Lewy bodies, which have long been thought to accompany the neurological condition in its later stages, according to a new study from U.S. researchers. The scientists found that most…

A growing body of research suggests that the gut microbiome — the community of bacteria and other microscopic organisms that live in the human digestive tract — may play key roles in the development and progression of Parkinson’s disease. Data suggest that it may be possible to develop Parkinson’s…

The U.S. Food and Drug Administration (FDA) has given Gain Therapeutics a green light to launch a clinical trial — to run across three continents — testing GT-02287, an oral therapy designed to prevent the formation of toxic protein clumps in Parkinson’s disease. The agency clearance follows positive early…

Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these participants received a new, commercial-ready formulation of the cell therapy designed to make future manufacturing and treatment…

There are few things more humbling than confidently giving someone credit for a job they didn’t do. That’s what happened to my family when an Ikea table suddenly showed up, fully assembled, in my aunt’s living room. Naturally, we assumed one of my cousins had put it together while everyone…